Credit Suisse Group Analysts Give Intercept Pharmaceuticals (ICPT) a $167.00 Price Target

Intercept Pharmaceuticals (NASDAQ:ICPT) has been given a $167.00 target price by Credit Suisse Group in a note issued to investors on Monday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Credit Suisse Group’s target price indicates a potential upside of 167.89% from the stock’s previous close.

ICPT has been the subject of a number of other reports. Cantor Fitzgerald upgraded Intercept Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $69.00 price objective for the company in a research report on Wednesday, November 1st. Deutsche Bank started coverage on Intercept Pharmaceuticals in a research report on Tuesday, December 12th. They set a “buy” rating and a $106.00 price objective for the company. Royal Bank of Canada restated an “outperform” rating on shares of Intercept Pharmaceuticals in a research report on Wednesday, October 4th. BidaskClub downgraded Intercept Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Tuesday, January 16th. Finally, JMP Securities reiterated an “outperform” rating and issued a $140.00 target price (down from $150.00) on shares of Intercept Pharmaceuticals in a report on Tuesday, September 26th. Four equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have issued a buy rating to the company’s stock. Intercept Pharmaceuticals presently has an average rating of “Hold” and an average price target of $138.62.

Intercept Pharmaceuticals (ICPT) opened at $62.34 on Monday. Intercept Pharmaceuticals has a 1 year low of $51.53 and a 1 year high of $135.59. The company has a debt-to-equity ratio of 3.15, a quick ratio of 5.95 and a current ratio of 5.95. The stock has a market capitalization of $1,560.00, a PE ratio of -4.21 and a beta of -2.05.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($3.48) by $0.59. Intercept Pharmaceuticals had a negative return on equity of 176.51% and a negative net margin of 344.74%. The company had revenue of $41.33 million during the quarter, compared to the consensus estimate of $36.95 million. During the same period last year, the company earned ($3.59) earnings per share. The firm’s revenue was up 697.9% compared to the same quarter last year. research analysts predict that Intercept Pharmaceuticals will post -13.36 EPS for the current fiscal year.

A number of institutional investors have recently made changes to their positions in the business. WFG Advisors LP grew its stake in Intercept Pharmaceuticals by 16.4% in the second quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 125 shares during the period. Voya Investment Management LLC boosted its position in shares of Intercept Pharmaceuticals by 4.7% during the second quarter. Voya Investment Management LLC now owns 6,994 shares of the biopharmaceutical company’s stock valued at $847,000 after buying an additional 313 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in shares of Intercept Pharmaceuticals by 23.3% during the second quarter. PNC Financial Services Group Inc. now owns 2,490 shares of the biopharmaceutical company’s stock valued at $302,000 after buying an additional 470 shares during the last quarter. Principal Financial Group Inc. boosted its position in shares of Intercept Pharmaceuticals by 3.1% during the second quarter. Principal Financial Group Inc. now owns 15,699 shares of the biopharmaceutical company’s stock valued at $1,901,000 after buying an additional 477 shares during the last quarter. Finally, Alliancebernstein L.P. boosted its position in shares of Intercept Pharmaceuticals by 6.2% during the second quarter. Alliancebernstein L.P. now owns 9,459 shares of the biopharmaceutical company’s stock valued at $1,145,000 after buying an additional 550 shares during the last quarter. 73.78% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This article was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at https://www.americanbankingnews.com/2018/01/22/credit-suisse-group-reaffirms-outperform-rating-for-intercept-pharmaceuticals-icpt.html.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply